Ignite Creation Date:
2024-05-06 @ 8:49 AM
Last Modification Date:
2024-10-26 @ 12:05 PM
Study NCT ID:
NCT02826512
Status:
TERMINATED
Last Update Posted:
2022-07-18
First Post:
2016-07-05
Brief Title:
A Feasibility Study of Niraparib for Advanced BRCA1-like HER2-negative Breast Cancer Patients
Sponsor:
The Netherlands Cancer Institute
Organization:
The Netherlands Cancer Institute
Study Overview
Official Title:
A Feasibility Study of Niraparib for Advanced BRCA1-like HER2-negative Breast Cancer Patients the ABC Study
Status:
TERMINATED
Status Verified Date:
2022-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not enough eligble patient can be found too many screen failures
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
Patients with locally recurrent BRCA1-like HER2-negative breast cancer that cannot be treated with curative intent by local treatment surgery radiotherapy - hyperthermia or patients with metastatic BRCA1-like HER2-negative breast cancer that have received a maximum of one prior line of treatment for incurable disease will be treated with Niraparib until disease progression
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None